Zai Lab Ltd (ZLAB)

Form 4 - Statement of changes in beneficial ownership of securities

Zai Lab Announces Changes to Senior Leadership Team

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need - Preliminary...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report